A multicenter, double-blind, randomized, active controlled study to compare the effect of 52 weeks treatment with vildagliptin 50 mg bid to pioglitazone 30 mg daily as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy

Registry ID

EUCTR2005-002199-14

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Pharma Services AG

Start date

2005-09-14

Completion date

2007-09-12

Last update

2026-08-16

Conditions

• Type II Diabetes
• Treatment of type 2 diabetes as monotherapy or in association with others oral anti-diabetic agents and/or insulin

Summary

To demonstrate the efficacy of add-on therapy with vildagliptin in patients with type 2 diabetes inadequately controlled with prior metformin monotherapy by testing the hypothesis that the HbA1c reduction with vildagliptin is not inferior to that with pioglitazone at Week 52.

Locations

• , , Italy
• , , Germany
• , , UK
• , , Austria
• , , Spain

Related clinical trials

• The GRoceries Aimed at Increasing Nutrition Study
• Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
• Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
• Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
• Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.

View on source registry